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Background: Puerto Rico is among the areas with the highest estimated rates of people
living with HIV in the United States. Despite the epidemiologic data available, there is
limited real-world information that can help understand the comorbidities of people with
HIV. In this study, we describe common comorbidities among adults with HIV attending
treatment clinics in Puerto Rico.
Methods: An exploratory, retrospective, cross-sectional study was conducted at ﬁve HIV
clinics in Puerto Rico. A random sample of medical records was reviewed. Descriptive
statistics were used to summarize patient demographics, morbidity, and clinical characteristics. Multivariate analyses were conducted to explore comorbidities by age and sex.
Results: A total of 250 (179 men; 71 women) medical records were reviewed. Participants’
mean age was 47.9 years and on average they had been living with HIV for 9 years. Most
(97.6%) had at least one comorbidity. The most common comorbidities were dyslipidemia
and hypertension. Men were more likely to have been diagnosed with alcohol misuse while
women were more likely to have been diagnosed with obesity, human papillomavirus (HPV),
hypothyroidism, and osteoporosis. Participants younger than 50 years of age were more
likely to have history of alcohol misuse while older individuals (50 years and old) were more
likely to have been diagnosed with dyslipidemia, hypertension, and diabetes. Adjusting by
sex and age, women were more likely to have been diagnosed with obesity and depression
and those older than 50 years were more likely to have had a diagnosis of dyslipidemia,
hypertension, HPV, and diabetes.
Conclusions: This is one of the few studies assessing comorbidities among adults with HIV in
Puerto Rico, among Latino/Hispanics within the United States, and Latin America. Consistent
with other studies, cardiovascular diseases are common among adults with HIV in Puerto Rico.
Findings support the need for awareness and real-world evidence about comorbidities among
people with HIV when implementing screenings and prescribing drugs.
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HIV continues to be a signiﬁcant public health issue, and despite advances in
prevention and care services, further work is needed to improve the well-being of
people living with HIV. Globally, in 2017, more than 940,000 people died of HIVrelated illnesses, 36.9 million were HIV-positive, and 1.8 million people became
newly infected.1 By 2015, and according to the Centers for Disease Control and
Prevention (CDC),2 Puerto Rico was among the areas with the highest estimated
rates of adults and adolescents with diagnosed HIV infection (17.1 per 100,000) in
the United States (US) and dependent areas. By May 2019, there were 49,675
known HIV infections in Puerto Rico.3 The incidence of HIV in the island is one of
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the highest rates in the United States4 and almost double
the overall US Hispanic/Latino population.5,6
In Puerto Rico, the number of HIV/AIDS cases and the
number of deaths have reduced substantially throughout
the years, lowering the case fatality rate from 82% in 1985
to 2% in 2016.7 Further, in a recent report by MarzánRodríguez and colleagues,8 it was documented that of all
the deaths among people with HIV in Puerto Rico from
2006 to 2011, less than a quarter (23.5%) were related to
HIV/AIDS.
People diagnosed with HIV infection may have an
increased risk of developing comorbidities compared to
the general population due to HIV disease itself and the
use of long-term antiretroviral therapy (ART).9–20 As HIV
survival has increased and persons living with HIV enjoy
life expectancies similar to those without HIV infection,
they are likely to share the same comorbidities. For example, heart disease is among the comorbidities typically
seen among people with HIV.21–24 Coincidentally, heart
disease was the second leading cause of death in Puerto
Rico in 2013.25 Furthermore, the Behavioral Risk Factor
Surveillance System (BRFSS) has evidenced relatively
high prevalence of high cholesterol (36.7), hypertension
(44.7), and diabetes (17.2%) among adult residents in
Puerto Rico.26 In addition, nearly two-thirds are either
overweight or obese, a risk factor for Coronary Heart
Disease (CHD), and 43.4% has been estimated to have
metabolic syndrome.27 In a recent assessment of CHD risk
of patients attending physician ofﬁces in Puerto Rico, a
substantial number of patients whose records were
reviewed had risk factors for developing CHD and nearly
one-third of the sample had a 10% or more 10-year risk of
developing CHD.28
In spite of the availability of mortality and prevalence
data, there is a lack of real-world published information
that would help to understand the comorbidities of people
with HIV in Puerto Rico. Such information is of great
importance to create awareness among health care providers and the health care system overall about the needs of
taking into consideration the comorbidities of people with
HIV when planning screening tests and prescribing any
medication that they may need.

Methods
To understand comorbidities in a sample of adult HIVpositive individuals in Puerto Rico, an exploratory, retrospective, cross-sectional study was conducted between
January and April 2015. Data were collected from ﬁve
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clinics that provide services to people with HIV in different geographical areas in Puerto Rico. Clinics were purposively chosen to provide diversity to the sample and based
on disposition to collaborate in the study. A State Health
Department HIV Clinic, a Municipal Health Department
HIV Clinic, and three private/non-governmental HIV
Clinics provided the sample for the study. Both publicly
funded and private-owned clinics were included.

Sample
A random sample of medical records was reviewed. At
each clinic, a simple random selection was used to select
medical records to be reviewed. The eligibility criteria to
select and review a medical record included having an
HIV diagnosis, at least 21 years of age, and being engaged
in care in the selected clinic during the last 6 months.
Patients with an AIDS diagnosis and pregnant women
were excluded from the study due to additional medical
conditions associated with their health status. Similarly,
individuals enrolled in clinical trials at the time of data
collection or during the last six months prior to their
medical chart revision were excluded from the sample.

Measurements
Following an extensive narrative literature review and clinician’s recommendations, an in-depth data collection instrument was created, allowing for the recollection of HIV
clinical information, as well as patient history of numerous
comorbidities, lipids, glucose and creatinine data, and
comorbidities treatment history. Patient’s demographic
information were also collected. All data collected were
based on the information available in the medical record
of each patient at the selected clinics. Comorbidities were
collected from the medical record using different sources of
information, including problem list, referral notes, and progress notes.

Analysis
Data collection was completed using a paper and pen
survey-like instrument, and then data were transferred to
an electronic dataset using the Questionnaire Development
System (QDS, Nova Research Company). Descriptive statistics (ie, mean, standard deviation) was used to summarize patient demographics, morbidity, and clinical
characteristics. Multivariate analyses (ie, MANOVA,
Multiple Regression Analysis) were conducted to explore
differences by age and sex. For age-related analysis, 50
years of age were selected to dichotomize the sample and
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this is consistent with CDC deﬁnition of older people with
HIV.29 SPSS v.20 was used to conduct all statistical procedures. Authorization was sought and received from each
clinic before submitting to the Institutional Review Board
(IRB). All study procedures were approved by the Human
Research Subjects Protection Ofﬁce of the University of
Puerto Rico-Medical Sciences Campus.

Results
Demographic and clinical characteristics
As included in Table 1, a total of 250 medical records were
reviewed. Of these, 179 were of men (71.6%) and 71
(28.4%) of women. The mean age of the subjects was
47.9 years and, on average, they had been living with
HIV for 9.3 years. Data availability for this research did
not differ by sex. Certainly, as a result of good practices in
HIV care, patients who have been living longer with a
diagnosis of HIV infection had more information in their
medical records.
On average, the age for HIV diagnosis among participants was 38 years; they spent 9.4 years from HIV diagnosis to treatment initiation and have been on treatment for
3.4 years. The mean CD4 count was 723.8 cells/mm3, and
for viral load, the count was 3,431.1 copies/mL.
Considering the role that body max index (BMI) may
have with certain comorbidities, bivariate analyses were
conducted to assess the BMI by sex and age. As included
in Table 2, more than a third of the study sample was
overweight. Among men, 62.6% had an abnormal BMI,

while 35.2% of the women were obese. These differences
were statistically signiﬁcant by sex.
When BMI was assessed by age groups (younger than
50 years of age and 50 years of age and older), more than a
third (37.0%) of those younger than 50 years of age had a
normal BMI, and 40.4% of those 50 years of age or older
were overweight. These differences by age groups were
not found to be statistically signiﬁcant. See Table 2 for
details.

Comorbidities
The vast majority (97.6%) of the participants had been diagnosed with at least one HIV comorbidity during the 6-month
period that preceded data collection. Among the most common comorbidities for both men and women were dyslipidemia (total: 60.8%; men: 60.8%; women: 69.0%), alcohol
abuse (total: 48.8%; men: 58.1%; women: 25.4%), and
hypertension (total; 39.6%; men: 36.9%; women: 46.5%).
Table 3 includes all the comorbidities found in the study
sample. In general, the mean amount of comorbidities
reported in the sample was 3.7 (SD=1.9). Men reported
signiﬁcantly less comorbidities (Mean=3.5, SD=1.9) than
women (Mean=4.1, SD=1.9; p=0.035).
As included in Table 3, when all comorbidities where
assessed by sex, men were more likely to have been
diagnosed with alcohol misuse (p<0.001) while women
were more likely to have been diagnosed with obesity
(p=0.001), HPV infection (p=0.002), hypothyroidism
(p=0.006), and osteoporosis (p=0.003).

Table 1 General characteristics of a sample of adults with HIV in Puerto Rico
Characteristics

Total (N=250)

Men (N=179)

Women (N=71)

μ

SD

μ

SD

Μ

SD

Age
Weight (lbs)

47.9
169.9

12.6
38.7

46.3
170.7

13.3
34.0

51.8
168.1

9.8
48.7

Height (in)

67.4

6.0

69.0

6.2

63.3

2.7

Body mass index
Age when diagnosed with HIV

26.6
38.0

6.0
11.6

25.5
37.0

5.0
12.0

29.3
40.6

7.4
9.8

Age of HIV treatment initiationa

39.6

12.5

37.7

13.1

44.7

9.3

Diagnosis to HIV treatment (months)a
Years living with HIV

9.4
9.3

17.1
8.1

9.0
8.8

15.5
8.0

10.6
10.6

20.8
8.0

Years in HIV treatmenta

3.4

3.6

3.0

3.6

4.2

3.4

Days since last CD4 test
CD4 count (cells/mm3)

80.2
723.8

75.7
363.2

79.8
698.7

65.2
326.8

81.1
786.6

97.6
437.6

CD4 percentage

34.8

30.4

34.6

35.1

34.9

30.4

Days since last viral load test
Viral load countb (copies/mL)

81.4
3431.1

84.6
14,342.9

82.7
4174.3

76.7
16,670.5

78.1
1628.7

102.2
5348.1

Notes: aN=103 (Men=74, Women=29). bn=137 (Men=97, Women=40).
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Table 2 Bivariate analysis of body mass index categorized by sex and age in a sample of adults with HIV in Puerto Rico
Comorbidity

Total (N=250)

Men (N=179)

Women (N=71)

N

%

n

%

n

%

<20
20–<25

26
84

10.4
33.6

21
67

11.7
37.4

5
17

25–<30

90

36.0

66

36.9

30+

50

20.0

25

14.0

<50 yrs (N=135)

50+ yrs (N=114)

n

%

n

%

7.0
23.9

12
50

8.9
37.0

14
33

12.3
28.9

24

33.8

44

32.6

46

40.4

25

35.2

29

21.5

21

18.4

Body mass index
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p-Value

0.001

p-Value

0.360

Note: Values in bold represent statistical signiﬁcance (<0.05).

Table 3 Comorbidities in a sample of adults with HIV in Puerto Rico
Comorbidity

Total

Men (N=179)

Women (N=71)

p-Value

n

%

n

%

N

%

Prevalence of comorbidities

244

97.6

174

97.2

70

98.6

0.519

Dyslipidemia
Alcohol miuse

152
122

60.8
48.8

103
104

57.5
58.1

49
18

69.0
25.4

0.094
<0.001

Hypertension

99

39.6

66

36.9

33

46.5

0.161

Cigarette Smoking
Overweight

89
67

35.6
26.8

67
46

37.4
25.7

22
21

31.0
29.6

0.337
0.532

Diabetes mellitus

49

19.6

32

17.9

17

23.9

0.276

Depression
Obesity

48
48

19.2
19.2

29
25

16.2
14.0

19
23

26.8
32.4

0.056
0.001

Substance misuse

42

16.8

33

18.4

9

12.7

0.272

Human papilloma virus (HPV)
Chronic hepatitis C

42
33

16.8
13.2

22
24

12.3
13.4

20
9

28.2
12.7

0.002
0.878

Vitamin D deﬁciency

24

9.6

15

8.4

9

12.7

0.298

Hypothyroidism
Chronic hepatitis B

20
12

8.0
4.8

9
7

5.0
3.9

11
5

15.5
7.0

0.006
0.330

Chronic kidney disease

10

4.0

5

2.8

5

7.0

0.153

Lipodystrophy
Osteoporosis

9
9

3.6
3.6

8
2

4.5
1.1

1
7

1.4
9.9

0.452
0.003

Benign prostatic hyperplasia
Peripheral vascular disease

7
6

2.8
2.4

7
5

3.9
2.8

–
1

–
1.4

–
0.999

Revascularization Procedure

6

2.4

4

2.2

2

2.8

0.999

Acute coronary syndrome (ACS)
Pre-diabetes

5
5

2.0
2.0

5
3

2.8
1.7

0
2

–
2.8

0.326
0.624

Angina pectoris

4

1.6

3

1.7

1

1.4

0.999

Previous stroke/TIA
Congestive heart failure

2
1

0.8
0.4

0
1

–
0.6

2
0

2.8
–

0.080
0.999

Note: Values in bold represent statistical signiﬁcance (<0.05).

The data collection instrument also included a general
clinical assessment of indicators of common comorbidities
and chronic conditions. As included in Table 4, data on
blood pressure, lipid panel, and blood chemistry tests were
obtained from medical records. Overall, the research sample showed slightly higher levels for triglycerides, glucose,
hemoglobin A1c, and systolic blood pressure when compared to normal values. When analyzed by sex, women
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had LDL levels slightly higher than normal. There were no
statistically signiﬁcant ﬁndings when these clinical indicators were assessed by age.
As included in Table 5, the most common comorbidity
treatments were multivitamins (71.5%), lipid-lowering therapy (57.6%), and antihypertensive agents (37.6%). These
were also the most common treatments when stratiﬁed by
sex. The mean amount of medications in the study sample
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Table 4 Blood pressure, lipid panel, and blood chemistry tests data from a sample of adults with HIV in Puerto Rico
Clinical indicator

a

Men (N=179)

Women (N=71)

μ

SD

Μ

SD

μ

SD

36.7

31.0

37.5

32.0

35.0

29.3

Total cholesterol
HDL

177.9
46.1

41.7
16.1

175.0
44.6

42.5
14.8

185.3
50.0

38.8
18.4

LDL

99.8

34.1

98.3

34.2

103.7

33.7

Triglycerides
Glucose (FPG)

185.7
101.6

179.1
33.1

191.3
101.4

194.9
31.3

171.7
101.9

131.7
131.7

Hemoglobin A1c (HgbA1c)b

6.1

1.5

6.2

1.7

6.1

0.9

Systolic

128.3

17.5

127.6

16.4

130.1

19.8

Diastolic

79.4

10.7

79.0

11.0

80.4

10.0

1.0

0.6

1.0

0.6

0.8

0.7

Non-HDL
HIV/AIDS - Research and Palliative Care downloaded from https://www.dovepress.com/ by 187.163.59.26 on 25-Jul-2019
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Total (N=250)

Blood pressure

Creatinine (Cr)
a

b

Notes: N=167 (Male=113; Female=54). n=93 (Male=65; Female=28).

Table 5 Treatment history of a sample of adults with HIV in Puerto Rico
Treatment

Total (N=250)

Men (N=179)

p-Value

Women (N=71)

n

%

n

%

n

%

Anti-acids

8

3.2

3

1.7

5

7.0

Antihyperglycemic agents

41

16.4

30

16.8

11

15.5

0.807

Antihypertensive agents
Asthma medications

94
28

37.6
11.2

63
17

35.2
9.5

31
11

43.7
15.5

0.213
0.175

0.030

Cholecalciferol

80

32.0

51

28.5

29

40.8

0.059

Dehydroepiandrosterone
H2 blockers

3
42

1.2
16.8

3
25

1.7
14.0

0
17

–
23.9

–
0.057

Levothyroxine

15

6.0

7

3.9

8

11.3

–

Lipid-lowering therapy
Multivitamins

144
178

57.6
71.5

97
123

54.2
68.7

47
55

66.2
78.6

0.083
0.121

Opioid pain medication

2

0.8

2

1.1

0

–

–

Proton pump inhibitors

46

18.4

21

11.7

25

35.2

<0.001

Note: Values in bold represent statistical signiﬁcance (<0.05).

was of 2.1 (SD =16). Men were using less medications
(Mean =2.5, SD =1.5) than women (Mean =3.5, SD =1.6,
p<0.001).
Further, when compared to men, women were more
likely to be using proton pump inhibitors (p<0.001) and
anti-acids (p=0.030, See Table 5).
To explore age-related factors associated with comorbidities, the sample was dichotomized in two age groups,
younger than 50 years of age and 50 years of age and
older. As included in Table 6, the group younger than 50
years were more likely to have an alcohol abuse diagnosis
(p=0.006) while the older individuals (50 years of age or
older) were more likely to have been diagnosed with

HIV/AIDS - Research and Palliative Care 2019:11

dyslipidemia (p<0.001), hypertension (p<0.001), and diabetes mellitus (p<0.001).
Considering the role of age in developing comorbidities,
a multivariate analysis adjusting by sex and age was conducted. Findings suggest that women were more likely than
men to have been diagnosed with obesity (aOR=3.197; 95%
CI: 1.625–6.290) and depression (aOR=1.986; 95% CI:
1.008–3.914). Also, as included in Table 7, they were
slightly more likely than men to have been diagnosed with
alcohol abuse (aOR=0.266; 95% CI: 0.143–0.496), HPV
infection (aOR=0.282; 95% CI: 0.136–0.584), and
hypothyroidism (aOR=0.300; 95% CI: 0.116–0.779).
Comorbidities associated with been older than 50 years of
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Table 6 Bivariate analysis of the prevalence of comorbidities by age in a sample of adults with HIV in Puerto Rico
Comorbidity

<50 yrs (N=135)

HIV/AIDS - Research and Palliative Care downloaded from https://www.dovepress.com/ by 187.163.59.26 on 25-Jul-2019
For personal use only.

n

%

N

%

Prevalence of comorbidities

131

97.0

113

99.1

0.242

Alcohol abuse
Dyslipidemia

77
66

57.0
48.9

45
86

39.5
75.4

0.006
<0.001

Cigarette smoking

55

40.7

34

29.8

0.073

Hypertension
Overweight

38
34

28.1
25.2

61
33

53.5
28.9

<0.001
0.505

HPV

28

20.7

14

12.3

0.076

Substance misuse
Obesity

27
27

20.0
20.0

15
21

13.2
18.4

0.151
0.753

Depression

27

20.0

21

18.4

0.753

Diabetes mellitus
Chronic hepatitis C

15
13

11.1
9.6

34
20

29.8
17.5

<0.001
0.067

Vitamin D deﬁciency

10

7.4

14

12.3

0.194

Hypothyroidism
Chronic hepatitis B

9
7

6.7
5.2

11
5

9.6
4.4

0.388
0.769

Angina pectoris

3

2.2

1

0.9

0.627

Chronic kidney disease
Revascularization procedure

3
2

2.2
1.5

7
4

6.1
3.5

0.193
0.417

Pre-diabetes

2

1.5

3

2.6

0.663

Lipodystrophy
Osteoporosis

2
2

1.5
1.5

7
7

6.1
6.1

0.084
0.084

Benign prostatic hyperplasiaa

2

1.9

5

7.1

0.114

Previous stroke/TIA
Peripheral vascular disease

1
1

0.7
0.7

1
5

0.9
4.4

0.999
0.096

Acute coronary syndrome (ACS)
Congestive heart failure

0
0

–
–

5
1

4.4
0.9

0.019
0.458

Tuberculosis

0

–

0

–

–

Fat accumulation

0

–

0

–

–

a

Notes: Only men were included when analyzing benign prostatic hyperplasia (n=178). Values in bold represent statistical signiﬁcance (<0.05).

age were dyslipidemia (aOR=3.075; 95% CI: 1.769–5.346),
hypertension (aOR=2.852; 95% CI: 1.670–4.871), HPV
infection (aOR=2.547; 95% CI: 1.205–5.385), and diabetes
mellitus (aOR=3.331; 95% CI: 1.684–6.589).

Discussion
While not a representative sample of people with HIV in
Puerto Rico, data from participants in this study are
similar to the general epidemiological data available of
people with HIV and to other studies conducted among
people with HIV in Puerto Rico. The ratio of women and
men with HIV in the sample (1:3) is consistent with
surveillance data from the Puerto Rico Department of
Health.7 Other general similarities with previously published research are participant’s average age30,31 and
hemoglobin levels.32
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Consistent with other studies among people with HIV, the
sample studied in this research evidenced comorbidities associated with cardiovascular diseases.33 For example, dyslipidemia is a comorbidity reported among other similar populations.
In our study, the prevalence of dyslipidemia was higher than
the rates reported among HIV-positive adults (43.7% Latinos)
in the Bronx, NY (60.8% vs 48%).33
The ﬁve most common comorbidities in this sample of
people with HIV in Puerto Rico slightly varied from the ﬁndings from a study published by Miranda and colleagues34 also
encompassing a sample of HIV-positive individuals in the
island. In their longitudinal study among people with HIV,
they found that the most common comorbidities were cardiovascular diseases, renal and hepatic disorders, osteopenia,
endocrine and metabolic abnormalities, and non-AIDS deﬁning neoplasm. The difference between these studies might be
the inclusion/exclusion of patients with an AIDS diagnosis and
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Table 7 Multivariate analysis of the prevalence of comorbidities by age and sex in a sample of adults with HIV in Puerto Ricoa
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Comorbidity

Sex

Age

Men

Women

<50 yrs

50+ yrs

Ref.

aOR (95% CI)

Ref.

aOR (95% CI)

Prevalence of comorbidities

1

1.258 (0.133–11.891)

1

3.313 (0.354–31.040)

Alcohol abuse

1

0.266 (0.143–0.496)

1

0.595 (0.349–1.013)

Dyslipidemia
Cigarette smoking

1
1

1.288 (0.697–2.379)
0.821 (0.450–1.498)

1
1

3.075 (1.769–5.346)
0.641 (0.374–1.098)

Hypertension

1

1.181 (0.658–2.119)

1

2.852 (1.670–4.871)

Overweight
HPV

1
1

1.162 (0.623–2.168)
0.282 (0.136–0.584)

1
1

1.177 (0.663–2.088)
2.547 (1.205–5.385)

Drug abuse

1

0.703 (0.312–1.581)

1

0.644 (0.320–1.298)

Obesity
Depression

1
1

3.197 (1.625–6.290)
1.986 (1.008–3.914)

1
1

0.700 (0.357–1.372)
0.785 (0.407–1.514)

Diabetes mellitus

1

1.118 (0.558–2.240)

1

3.331 (1.684–6.589)

Chronic hepatitis C
Vitamin D deﬁciency

1
1

0.790 (0.340–1.836)
0.706 (0.288–1.733)

1
1

2.085 (0.971–4.474)
0.611 (0.255–1.462)

Hypothyroidism

1

0.300 (0.116–0.779)

1

0.859 (0.331–2.230)

Chronic hepatitis B
Angina pectoris

1
1

1.990 (0.591–6.707)
1.020 (0.100–10.432)

1
1

0.727 (0.217–2.439)
0.388 (0.038–3.941)

Chronic kidney disease

1

2.175 (0.592–7.992)

1

2.461 (0.603–10.047)

Revascularization procedure
Pre-diabetes

1
1

1.046 (0.181–6.054)
1.513 (0.237–9.656)

1
1

2.398 (0.418–13.768)
1.655 (0.261–10.516)

Lipodystrophy

1

0.217 (0.026–1.808)

1

5.348 (1.073–26.656)

Osteoporosis
Peripheral vascular disease

1
1

7.831 (1.548–39.622)
0.345 (0.039–3.075)

1
1

2.929 (0.573–14.986)
7.202 (0.816–63.535)

Notes: aAcute coronary syndrome, congestive heart failure, tuberculosis, previous stroke/TIA, and fat accumulation were excluded from this analysis due to lack of
reported cases in certain subgroups. Benign prostatic hyperplasia was also excluded from the analysis. Values in bold represent statistical signiﬁcance (<0.05).

the longitudinal nature of the study conducted by Miranda and
colleagues.34 It is our understanding that our ﬁndings illustrate
a better picture of the comorbidities of people with HIV in
Puerto Rico who are engaged in care.
Another study conducted among people with HIV in
Puerto Rico found morbidity and mortality associated with
kidney disease.30 However, in this sample, history of
comorbidity with kidney disease was low (<20%) and no
alarming levels of clinical indicators of kidney disease (ie,
creatinine) were reported.
Consistent with other research ﬁndings from studies
with people with HIV, when compared to men, women
show higher rates of overweight and obesity.31,35 A study
conducted by Ramirez-Marrero and colleagues36 reported
the risk for metabolic syndrome among people with HIV
in Puerto Rico. Consistent with their ﬁndings, our analysis
supports the needs for monitoring cardiovascular indicators among people with HIV. Furthermore, our ﬁndings –
consistent with those of Maldonado-Martínez and
colleagues35 from a sample of people with HIV in Puerto

HIV/AIDS - Research and Palliative Care 2019:11

Rico – support the needs for comprehensive approaches to
reduce the risk for metabolic syndrome and HIV disease
progression, including monitoring BMI as well as chronic
and behavioral precursors.
The most common comorbidities found in older groups
after controlling by sex are consistent with ﬁndings
reported in the scientiﬁc literature. A signiﬁcant ﬁnding
in this regard is the fact that dyslipidemia among those
participants 50 years and older was 3.075 (95% CI: 1.769–
5.346) more common than among those younger than 50
years. This is more than double the likelihood of this
correlation (OR=1.42) found in a sample of individuals
45 years or older from The Bronx, New York.33 Future
studies among patients older than 50 years are recommended to assess HIV-induced accelerated aging.
While the purpose of this study was not to assess HIV
comorbidities with mental illnesses in details, signiﬁcant
rates of depression and substance abuse were found. Due
to the fact that injecting drug use is one of the main risk
factors for HIV infection in Puerto Rico, it is not surprising
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to identify these comorbidities in a sample of people with
HIV in the archipelago. In our study, 48.8% of the sample
reported alcohol misuse. In other studies of people with
HIV, alcohol use had varied from 5% (measuring alcohol
abuse) to 51.5%.32,33,37 Nonetheless, different from other
investigations conducted in Puerto Rico,34,35 in our study
we found that, after adjusting by age and sex, women had
higher likelihood of been diagnosed with alcohol misuse.
This ﬁnding, as other ﬁndings reported in this manuscript,
requires further analysis considering the role that sex differences may play in access and healthcare use.38
On the other hand, cigarette smoking was reported
among more than a third of the participants (35.6%) and
substance misuse was documented in 16.8% of the study
sample. Other studies have reported rates from 13% to
59.4% of cigarette smoking33,36,39 and from 3% (reporting
only drug abuse) to 43.7% of substance misuse.32,33 The
ﬁndings of our study are consistent with those from other
studies reporting higher rates of substance misuse (nonalcohol or cigarettes) among men.34,35
Findings from this study should be considered in context with population-based data available regarding the
most common comorbidities in Puerto Rico. For example,
it has been documented that among adults in Puerto Rico
(irrespective of their HIV status) about 36.7% (36.6%
among men; 36.7% among women) have reported a high
level of cholesterol in blood;13.1% (20.5% among men;
6.8% among women) have reported binge drinking; 11.3%
have reported current smoker status (16.9% among men;
6.4% among women); and 68.3% of the population is
overweight or obese (70.2% among men; 66.6% among
women).26 These population trends have an impact in the
assessment of comorbidities among people with HIV in
Puerto Rico and the interpretation and comparisons with
ﬁndings from studies conducted with populations elsewhere. Moreover, these population health indicators highlight the signiﬁcance of the ﬁndings of this study and the
need to integrate public health prevention efforts.
Research ﬁndings should be considered within the limitations of this study. This research project was limited to
the revision of 250 medical charts from 5 clinics. These
clinics were selected following a purposive sampling
approach and the 250 medical charts reviewed were chosen based on a simple random selection. Further, due to
the retrospective and cross-sectional nature of this study,
data are limited to the information available from the chart
reviews. No data were collected related to the use of ART
limiting the analysis of the relationship of HIV-related
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medication and comorbidities. Similarly, the charts
selected for revision are of those participants who met
inclusion criteria and were active in medical care. As a
result of all the aforementioned limitations, ﬁndings are
not generalized to people with HIV in Puerto Rico or
elsewhere.

Conclusion
Based on a comprehensive narrative analysis of the scientiﬁc literature, and to the best of our knowledge, this is the
ﬁrst observational study that assessed comorbidities
among people with HIV in Puerto Rico and one of the
few among Latino/Hispanic populations. Despite the limitations of the study and consistent with other studies,
cardiovascular diseases – speciﬁcally dyslipidemia and
hypertension – were found to be common among people
with HIV in Puerto Rico. Certain characteristics such as
age, sex, and use of medication may play a role in the
comorbidities among people with HIV in Puerto Rico.
Findings support the need for creating awareness of the
comorbidities of people living with HIV, particularly when
implementing prevention strategies and prescribing drug
therapy. Further, this information should be available to
physicians and other health care providers to improve
differentiated and comprehensive approaches to address
the needs of people with HIV.
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Abbreviation list
AIDS, acquired immune deﬁciency syndrome; ART, anti-retroviral therapy; BMI, body mass index; BRFF, Behavioral
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Risk Factors Surveillance System; CD4, cluster of differentiation 4; CHD, coronary health disease; FPG, fasting plasma
glucose; HDL, high-density lipoprotein; HgbAic, glycosylated
hemoglobin; HIV, human immunodeﬁciency virus; HPV,
human papilloma virus; H2 blockers, histamine H2-receptor
antagonists; LDL, low-density lipoprotein; QDS,
Questionnaire Development System; SD, standard deviation;
TIA, transient ischemic attack; US, United States.
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